



OPEN

# Survey of drug resistance associated gene mutations in *Mycobacterium tuberculosis*, ESKAPE and other bacterial species

Abhirupa Ghosh<sup>1,2</sup>, Saran N.<sup>1,2</sup> & Sudipto Saha<sup>1</sup>✉

Tuberculosis treatment includes broad-spectrum antibiotics such as rifampicin, streptomycin and fluoroquinolones, which are also used against other pathogenic bacteria. We developed Drug Resistance Associated Genes database (DRAGdb), a manually curated repository of mutational data of drug resistance associated genes (DRAGs) across ESKAPE (i.e. *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.) pathogens, and other bacteria with a special focus on *Mycobacterium tuberculosis* (MTB). Analysis of mutations in drug-resistant genes listed in DRAGdb suggested both homoplasy and pleiotropy to be associated with resistance. Homoplasy was observed in six genes namely *gidB*, *gyrA*, *gyrB*, *rpoB*, *rpsL* and *rrs*. For these genes, drug resistance-associated mutations at codon level were conserved in MTB, ESKAPE and many other bacteria. Pleiotropy was exemplified by a single nucleotide mutation that was associated with resistance to amikacin, gentamycin, rifampicin and vancomycin in *Staphylococcus aureus*. DRAGdb data also revealed that mutations in some genes such as *pncA*, *inhA*, *katG* and *embA,B,C* were specific to *Mycobacterium* species. For *inhA* and *pncA*, the mutations in the promoter region along with those in coding regions were associated with resistance to isoniazid and pyrazinamide respectively. In summary, the DRAGdb database is a compilation of all the major MTB drug resistance genes across bacterial species, which allows identification of homoplasy and pleiotropy phenomena of DRAGs.

There is a rise in the use of broad spectrum antibiotics such as rifamycins, aminoglycosides and fluoroquinolones against tuberculosis (TB), as well as common bacterial infections such as gastro-intestinal infections<sup>1–3</sup>. The multi- and extensively drug-resistant (MDR and XDR) *Mycobacterium tuberculosis* (MTB) pose a global threat to public health as new resistance mechanisms are developing and making the treatment for patients prolonged and expensive. Drug resistance is not restricted to TB, but also observed in common bacterial infections such as pneumonia and foodborne infections<sup>4,5</sup>. Genome-wide analysis of MDR and XDR MTB reveals that drug resistance arises due to mutations in the gene and/or the promoter region. Drug resistance associated mutations are linked to increasing drug efflux, modifications of the drugs or their targets<sup>6–8</sup>. The accessibility to next-generation sequencing technologies and characterization of bacteria specific drug resistance allows the extensive study of other pathogenic bacteria as well<sup>9–11</sup>. Antibiotic resistance mutations specific to pathogenic bacteria are available. The Infectious Diseases Society of America has grouped *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter* spp. as ESKAPE pathogens that are capable of ‘escaping’ the actions of antibiotics thereby developing antibiotic resistance<sup>12</sup>. The ESKAPE pathogens are the leading cause of Hospital-Acquired Infection (HAI) or nosocomial infection<sup>13</sup>. Thus, it is important to understand the drug resistance mutations across ESKAPE species against tuberculosis drugs. Three major databases, Tuberculosis Drug Resistance Mutation database (TBDReaMDB), MUtation BioInformatics Identification (MUBII-TB-DB), Tuberculosis Drug resistance Database (TBDR) are currently available for mutations associated with drug resistance in MTB<sup>14–16</sup>. TBDReaMDB lists information on mutations in 51 genes across both first and second line TB drugs<sup>14</sup>. The major drawback of this database is that it has not been updated after 2009. Other databases such as MUBII-TB-DB and TBDR cover only a small set of genes<sup>15,16</sup>.

<sup>1</sup>Division of Bioinformatics, Bose Institute, Kolkata, India. <sup>2</sup>These authors contributed equally: Abhirupa Ghosh and Saran N. ✉e-mail: [ssaha4@jcbose.ac.in](mailto:ssaha4@jcbose.ac.in)

Drugs	Genes	No. of mutations			No. of Novel mutations* in DRAGdb
		DRAGdb	TBDReaMDB	MUBII-TB-DB	
Ethambutol	<i>embA,B,C</i>	273	11	—	56
Fluoroquinolone	<i>gyrA</i>	105	17	17	1
	<i>gyrB</i>	69	18	16	—
Isoniazid	<i>inhA</i>	30	13	11	17
	<i>katG</i>	542	273	—	55
Pyrazinamide	<i>pncA</i>	1200	278	277	125
Rifampicin	<i>rpoB</i>	710	133	130	32
Streptomycin	<i>gidB</i>	178	21	—	37
	<i>rpsL</i>	113	16	—	6
	<i>rrs</i>	201	25	7	26

**Table 1.** *Mycobacterium tuberculosis* (MTB) gene mutations reported in DRAGdb compared with TBDReaMDB and MUBII-TB-DB. \*Reported only in DRAGdb.

Prolonged usage of broad spectrum antibiotics against TB may affect the lung microbiome as well as the intestinal microbiome, which are connected by the “gut-lung axis”<sup>17–20</sup>. In addition, there may be potential horizontal transfer of antibiotic resistant genes in the human microbiome<sup>21–23</sup>. Therefore, there is a need to combine the information from all organism-specific studies into a single platform to have a complete idea of antibiotic resistance associated mutations across bacterial species. In order to facilitate the characterization of mutations in Drug Resistance Associated Genes (DRAGs) across bacterial species, we present DRAGdb, a manually curated database that has enlisted DRAG mutations across bacterial communities focusing on drugs used to treat tuberculosis. DRAGdb provides mutation information related to 6 drugs, a few of which are broad spectrum antibiotics and 12 associated genes across bacterial species including MTB, ESKAPE and other pathogens such as *Escherichia coli* and *Salmonella enterica*. It also provides drug resistance patterns of non-pathogenic bacteria including *Staphylococcus epidermidis* and *Bifidobacterium species*<sup>24,25</sup>. The mutational gene data analysis of DRAGdb highlights the concepts of homoplasy and pleiotropy<sup>26</sup>. Homoplasy is described as a phylogenetic event when a resistance determining mutation arises in phylogeny under selection pressure across species or strains<sup>27</sup>. Another major phylogenetic event occurs when a resistance determining mutation causes pleiotropic effects on resistance to other drugs in a bacteria due to resistance selection<sup>28</sup>. In summary, DRAGdb is a manually curated database of drug resistant genes of bacteria with a focus on TB drugs, which reveals that at least 6 genes carry drug resistance mutations across bacterial species, whereas some drug resistance genes are specific to *Mycobacterium species*.

## Results

**Overview of DRAGdb.** *Database content.* DRAGdb is a database of mutational information of DRAGs across MTB clinical strains, ESKAPE bacteria and other pathogenic and non-pathogenic bacterial species with special reference to MTB H37Rv. A systematic curation of mutations found in drug resistant bacteria from existing literature was compiled to create the database. Each mutation entry comprises of organism name, gene name and corresponding identifier from Ensembl Bacteria database, the nucleotide position, the nucleotide change, the amino acid codon position, the codon change, the type of mutation at the amino acid level, the sequencing method used to detect the mutation, the strain of the bacterial species, the geographical location of the sample and PubMed identifier of the literature referred to. The PROVEAN scores predicting the functionality of gene-mutations in different bacteria were added in DRAGdb and the full list of each entry is available in Supplementary File. 2. DRAGdb contains 4653 mutation entries associated with 12 genes and 6 drugs across 126 bacterial species.

**DRAGdb statistics.** The basic statistics of DRAGdb is shown in Tables 1 and 2. In Table 1, the MTB gene mutations were compared with existing MTB mutation databases such as TBDReaMDB and MUBII-TB-DB. It was observed that DRAGdb has comparatively higher numbers of mutations for each gene than the other two databases. Table 2 includes MTB genes that were also observed in ESKAPE pathogens and other pathogenic and non-pathogenic bacterial species.

**Mutation trends from DRAGdb.** The literature survey led to compilation of mutational data across different bacterial species for the genes such as *gidB*, *gyrA*, *gyrB*, *rpoB*, *rpsL* and *rrs* (Table 3). Mutations in these genes associated with drug resistance were observed in different bacterial species. However, the genes *inhA*, *katG*, *embA*, *embB*, *embC* and *pncA* are specific to *Mycobacterium species*. The genes associated with drug resistance across different bacterial species, were re-numbered using multiple sequence alignment at codon level with reference to MTB H37Rv, in order to obtain the most frequently mutated codon positions. The frequencies of important drug resistance associated mutations with positions at codon level are represented in bar plots for *gyrA*, *gyrB*, *rpoB*, and *rpsL* in Fig. 1(A–D).


**Common set of drug resistance genes across bacterial species.** DRAGdb focuses on drugs associated with TB treatment regimens, and lists mutations in associated genes across bacterial genera. It also lists drug resistance genes that are specific to MTB. MTB is relatively “young” from an evolutionary standpoint. It does not

Drugs	Genes	Bacterial Pathogens	No. of mutations
Fluoroquinolone	<i>gyrA</i>	ESKAPE	41
		Others	282
	<i>gyrB</i>	ESKAPE	39
		Others	168
Rifampicin	<i>rpoB</i>	ESKAPE	73
		Others	346
Streptomycin	<i>gidB</i>	ESKAPE	2
		Others	116
	<i>rpsL</i>	ESKAPE	4
		Others	129
	<i>rrs</i>	ESKAPE	—
		Others	13

**Table 2.** ESKAPE and other bacterial species gene mutations reported in DRAGdb.

Gene	No. of organisms	No. of drugs
<i>gidB</i>	13	01
<i>gyrA</i>	51	14
<i>gyrB</i>	41	13
<i>rpoB</i>	62	15
<i>rpsL</i>	37	04
<i>rrs</i>	07	08

**Table 3.** Genes associated with resistance across a variety of organisms and resistance to a number of drugs.



**Figure 1.** (A–C) The frequency plots for *gyrA*, *gyrB* and *rpoB* respectively show mutational frequencies in the top codon positions among all antibiotic resistance determining region codons in each gene. The frequency bars are plotted for ESKAPE pathogens, *Mycobacterium* species and all other bacterial species in each gene. (D) The frequency plot of *rpsL* shows mutational frequency of top codon positions among all reported codon positions of mutation. RRDR stands for Rifampicin Resistance Determining Region; QRDR stands for Quinolone Resistance Determining Region.

carry plasmids and is thus thought not to be engaged in horizontal gene transfer. However, it was observed that mutations in DRAGs of MTB and other bacterial species including ESKAPE pathogens, and other pathogenic and non-pathogenic bacteria, occur usually at the same codon position.

*gidB*. *gidB* also known as *rsmG*, was found to be associated with streptomycin resistance across 13 bacterial species including *Mycobacterium species*, an ESKAPE pathogen i.e. *S. aureus* and other bacteria.

*gyrA*. DRAGdb lists *gyrA* mutations associated with resistance to second and third generation fluoroquinolones, nalidixic acid and triclosan. *gyrA* mutations were found in 42 bacteria including different *Mycobacterium species*, all 6 ESKAPE pathogens and other bacterial species. The frequency plot of 3 important mutations in the Quinolone Resistance Determining Region (QRDR) of *gyrA* at codon positions 90, 91 and 94 is shown in Fig. 1A and the data is shown in Supplementary File 1: Table S1. The data shows that mutation at the 90<sup>th</sup> codon position was more dominant in ESKAPE pathogens whereas mutations at the 91<sup>st</sup> and 94<sup>th</sup> codon positions occurred more frequently in drug resistant MTB.

*gyrB*. Similar to *gyrA*, *gyrB* was also related to fluoroquinolone resistance. DRAGdb indicates that similar to *gyrA*, most of the *gyrB* mutations were associated with resistance to nalidixic acid and various fluoroquinolones. However, some *gyrB* mutations were associated with resistance to aminocoumarins, a group of gyrase inhibitors which include novobiocin and coumermycin. *gyrB* mutations were found in 36 bacteria including different *Mycobacterium species*, 5 ESKAPE pathogens and other bacterial species. The frequency plot of 4 important mutations in the QRDR of *gyrB* is shown in Fig. 1B and the data is shown in Supplementary File 1: Table S2. The codon at the 499<sup>th</sup> position was most frequently mutated in ESKAPE, MTB as well as other drug resistant bacteria.

*rpoB*. DRAGdb indicates that mutations in *rpoB* were not only responsible for resistance to the rifamycin class of drugs including rifampicin, rifabutin, rifalazil, rifapentine and rifaximin, but also resistance to 10 other drugs of various drug families in 62 bacterial species including *Mycobacterium species*, the ESKAPE pathogens *Acinetobacter baumannii*, *Enterococcus faecium*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and many other bacteria. The frequency plot of 3 crucial mutations in the Rifampicin Resistance Determining Region (RRDR) of *rpoB* (as shown in Fig. 1C and in Supplementary File 1: Table S3) shows that mutations at codon positions 435, 445 and 450 exerted an additive effect on drug resistance. Thus no single dominant mutation is alone responsible for resistance to rifamycins in MTB and ESKAPE.

*rpsL*. *rpsL* is primarily associated with streptomycin resistance. However, mutations in *rpsL* also cause resistance to other aminoglycosides such as kanamycin, amikacin and paromomycin. *rpsL* mutations were present across 37 bacteria including *Mycobacterium species*, an ESKAPE pathogen *Klebsella pneumoniae* and other bacterial species. The frequency plot of two dominant drug resistance associated mutations in *rpsL* at codon positions 43 and 88 is shown in Fig. 1D and the data is shown in Supplementary File 1: Table S4.

*rrs*. *rrs* encodes 16S rRNA in bacteria and is associated with streptomycin resistance. DRAGdb shows its involvement in resistance to 5 other aminoglycosides as well. Mutations in *rrs* were found in 7 bacterial species. No mutation has been reported for the ESKAPE pathogens.

**Homoplasy and pleiotropy.** Multiple sequence alignments of the protein sequences corresponding to each gene across the reported bacteria were performed as shown in Supplementary File 1: Fig. S1(A–D). Interestingly, in some genes such as *rpoB*, *gyrA*, *gyrB*, *gidB* and *rpsL* similar points of mutations associated with drug resistance, were observed across bacterial species. This could be due to common mechanisms associated with the bacterial response to an antibiotic/drug<sup>29</sup>. Such occurrence of identical genotypes across drug resistant bacterial species is termed here as homoplasy. The MTB H37Rv numbering system was used as reference in our analysis. An example of homoplasy is a point mutation, **Asp to Asn** in *rpoB* at codon position 435 (MTB numbering). This mutation was found in 12 bacterial species including MTB, ESKAPE pathogens such as *Actinobacter baumannii* and *S. aureus*, other pathogenic bacteria including *Helicobacter pylori* and *Haemophilus influenzae* and non-pathogenic bacteria, for example, *Deinococcus radiodurans* and *Streptomyces lividans*. In Fig. 2A, the circular plot illustrates some examples of homoplasy events in mutated codon positions across some of the reported bacterial species.

The data curated for DRAGdb also indicates in some bacteria, the presence of cross resistance towards multiple drugs due to a single point mutation. This phenomenon in which a single locus influences resistance to two or more distinct drugs is defined here as pleiotropy. Some of the mutations in *rpoB* across bacterial species were known to be associated with resistance to rifampicin and/or other rifamycins. However, an instance was found in *S. aureus* where mutation in *rpoB* at codon position 477 and nucleotide position 1430 (*S. aureus* numbering) was responsible for resistance to rifampicin, daptomycin, vancomycin and oxacillin<sup>30</sup>. In Fig. 2B, the circular plot provides examples of nucleotide positions in genes in specific organisms where a single point mutation is associated with multi-drug resistance.

**Drug resistance genes specific to MTB.** MTB is assumed to engage very little in horizontal gene transfer and thus considered inert or relatively young in evolutionary terms<sup>31</sup>. It also has an additional layer in its outer membrane composed of novel lipids and polysaccharides such as mycolic acid that makes it an acid fast bacterium<sup>32</sup>. The frequency analysis of 4 *Mycobacterium* specific genes with mutation entries, namely; *inhA*, *embB*, *katG* and *pncA* are shown in Fig. 3(A–D) and numbers are shown in Supplementary File 1: Tables S5–S8. Other than *katG*, all three lacked specific drug resistance determining regions. Drug resistance associated mutations were present all through their coding and non-coding (promoter) regions. Mutation type distribution in



*inhA*. *inhA* codes for enoyl-ACP reductase and is the primary target of the first-line tuberculosis drug isoniazid<sup>33</sup>. Mutations in the -8 and -15 positions in the promoter region of *inhA* were found in 44% of the isoniazid resistant clinical isolates of *Mycobacterium species*. The frequency plot is shown in Fig. 3A and the data is shown in Supplementary File 1: Table S5. The distribution of mutation types in *inhA* associated with isoniazid resistance is shown in Supplementary File 1: Figure S2A and Table S9.

*embB*. *embB* codes for arabinosyl transferase, an enzyme that plays a role in the polymerization of arabinose into the arabinan of arabinogalactan<sup>34</sup>. It is one of the primary targets of the first line tuberculosis drug ethambutol. Ethambutol inhibits the transfer of arabinogalactan to the cell wall. Mutations in codons 306 and 406 were found in 25% of the ethambutol resistant MTB as shown in Fig. 3B. The data is shown in Supplementary File 1: Table S6. The mutations were mainly observed in the coding region of *embB* as shown in Supplementary File 1: Figure S2B and Table S10.

*katG*. *katG* encodes for a bifunctional enzyme with both catalase and peroxidase activity. It plays a role in protecting *Mycobacterium* against toxic reactive oxygen species as well as in activating the first line drug isoniazid<sup>35,36</sup>. Mutations in 6 codon positions taken together account for 40% of the drug resistant clinical isolates as shown in Fig. 3C. The data is shown in Supplementary File 1: Table S7. Mutation at codon 315 was found in 30% of drug resistant MTB. The distribution of mutation types in *katG* associated with isoniazid resistance is shown in Supplementary File 1: Figure S2C and Table S11.


*pncA*. *pncA* gene codes for pyrazinamidase, which converts the first line tuberculosis drug, pyrazinamide into its active form, pyrazinoic acid<sup>37</sup>. Mutations in *pncA* and its promoter region results in resistance to pyrazinamide. On comparing mutations from pyrazinamide resistant clinical strains of *Mycobacterium species*, it was observed that the mutations were scattered throughout the promoter and the coding region. Overall, 11 sites of mutation accounted for 21% of the mutations in clinical isolates of *Mycobacterium species*. This is shown in Fig. 3D and data is given in Supplementary File 1: Table S8. The mutations in *pncA* were observed to be diverse in nature (shown in Supplementary File 1: Figure S2D and Table S12).

**Comparison with other databases and tools.** There are several antibiotic resistance related databases as listed in Supplementary File 1: Table S13 obtained from PubMed literature search. The contents of the databases such as the bacterial species focused, data types, availability of mutation data were thoroughly studied and compared. Out of these 17 databases, three were beta-lactamases related resources<sup>38–40</sup>, five were specific to single species such as uCARE<sup>41</sup> is for *E.coli* and TBDB, ReSeqTB<sup>42</sup>, TBDRearMDB and MUBII-TB-DB were dedicated to MTB. A comparison of TBdreamDB and MUBII-TB-DB, two well-known databases for mutations associated with drug resistance in MTB with DRAGdb is presented in Table 1. DRAGdb lists a higher number of gene mutations. There were nine multispecies antimicrobial databases. Among them, MEGARes<sup>43</sup>, BacMet<sup>44</sup>, Resfams<sup>45</sup> and Pathosystems Resource Integration Center (PATRIC)<sup>46</sup> contain bacterial genome and drug resistance genes but no mutation data is available in them. There were two deprecated databases such as ARG-ANNOT<sup>47</sup> and ARDB - Antibiotic Resistance Genes Database<sup>48</sup>, however, ARG-ANNOT gene list is incorporated in MEGARes and ARDB is upgraded as CARD<sup>49</sup>. Finally it was observed that only three databases contain updated drug resistance causing mutation data across species namely; CARD, BARRGD<sup>50</sup> and PointFinder<sup>51</sup>. The mutation data available in these three databases were downloaded for further analysis. A case study to compare the *rpoB* gene mutations associated with drug resistance in MTB and ESKAPE pathogens along with *Mycobacterium leprae*, *Escherichia coli*, *Enterococcus faecalis* present in these three databases and DRAGdb was done. A venn diagram in Fig. 4 shows that DRAGdb had 174 unique SNPs in *rpoB* gene compared to other three databases. The unique list of *rpoB* mutations in DRAGdb as shown in supplementary File. 3 comprises mainly of mutations in bacteria like *Enterococcus faecium*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterococcus faecalis* that were only available in DRAGdb and few mutation points in other bacteria also. There are also some tools for the prediction of antibiotic resistance genes such as meta-MARC that predicts drug resistance from metagenomics data<sup>52</sup>, and AMRFinder that uses hidden Markov model of BARRGD sequence database to identify the genes related to drug resistance<sup>53</sup>. DRAGdb use its own drug resistance associated gene sequence database at bacterial species level for Basic Local Alignment Search Tool (BLAST) search. Thus it allows users to identify the best hit mutant sequence at species level. This cannot be achieved with AMRFinder.


**Utility and limitations of DRAGdb.** The benefit of DRAGdb is that it provides information on antibiotic resistance related mutations across various bacterial species in a single platform. As shown in the schematic diagram of DRAGdb in Fig. 5, in addition to browsing the mutation database, the BLAST tool is integrated for prediction of drug resistance from a query sequence. Compared to existing databases, DRAGdb contains higher numbers of, as well as unique drug resistance associated gene mutations as shown in Table 1. The caveat of this version of DRAGdb, is that all the double or multiple mutations in a drug resistant gene are considered as separate entries for each species and thus the overall effect of all drug resistant mutations is not presented in a comprehensive manner in a specific search. Further, the effect of mutations in multiple genes in MDR, for example *gyrA* and *rpoB*, cannot be obtained in a single search. However, the BROWSE page of DRAGdb allows users to get all the information in tabular format.

## Discussion

In the recent past, due to the increasing availability of next generation technologies, a large number of studies have been carried out to unravel the specificity of drug resistance in many pathogenic bacteria. Here, we describe DRAGdb a database that contains mutational data across MTB, ESKAPE pathogens, other pathogenic bacteria such as those causing sexually transmitted infections (*Neisseria gonorrhoeae*), foodborne



**Figure 4.** The venn diagram for the comparison of *rpoB* mutations in MTB and ESKAPE pathogens along with *Mycobacterium leprae*, *Escherichia coli*, *Enterococcus faecalis* among CARD, BARRGD, PointFinder and DRAGdb. BARRGD has *rpoB* mutations of Proteobacteria at phylum level thus it has no common entry at species level.



**Figure 5.** Schematic architecture of DRAGdb online database.

infections (*Campylobacter jejuni*), skin infections (*Streptococcus pyogenes*), and non-pathogenic organisms such as *Bifidobacterium species*. Compared to the existing TB mutation databases such as TBDR, MUBII-TB-DB and TBDR, DRAGdb data carries more extensive mutational data<sup>14-16</sup>. DRAGdb data indicates the presence of similar mutation patterns in 6 drug resistant genes, namely *rpoB*, *gyrA*, *gyrB*, *gidB*, *rrs* and *rpsL* across bacterial ecosystems, that in turn highlights the drawbacks of using broad spectrum antibiotics for prolonged treatment of diseases such as tuberculosis<sup>1-5</sup>. We suggest that prolonged exposure to drugs required for the treatment of TB, leads to occurrence of resistance across bacterial populations in the gut microbiome that may hinder treatment of other bacterial infections<sup>20</sup>. However, on a positive note, identifying a common cause of resistance across a wide range of bacterial species opens up the possibility of designing diagnostic tools and identifying specific drug targets for a wide range of bacterial infections. The data presented here points to the occurrence of resistance in many pathogenic bacterial species along with the MTB clinical strains, the ESKAPE pathogens and commensal or non-pathogenic bacteria. There is an urgent need to focus on the purportedly under-rated pathogens which may cause severe health problems in the near future due to homoplasy and pleiotropy. DRAGdb also indicates that for the MTB specific drug resistance genes *pncA*, *inhA*, *katG* and *embA*, *B*, *C* in addition to the non-synonymous mutations in coding region, the non-coding regions also play important roles associated with drug resistance. This brings an additional layer of complexity to the mechanisms of drug resistance. Further, a systematic analysis of mutations responsible for drug resistance in a bacterial community against specific drugs, is required to understand the evolution in drug resistance genes in response to drug exposure.

## Conclusions

Antibiotic/drug resistance is a natural phenomenon in microbial populations and is a global health threat making the usage of antibiotics to treat life threatening infections such as tuberculosis and pneumonia less and less effective. Tuberculosis treatment requires broad spectrum antibiotic classes such as rifamycins, aminoglycosides and fluoroquinolones that are also extensively used against other bacterial infections. To contribute towards the analysis of the development of antibiotic/drug resistance we have developed the DRAGdb database. It is a free online repository of mutations in genes associated with broad spectrum antibiotics across *Mycobacterium species*, ESKAPE pathogens and other pathogenic and non-pathogenic bacteria, along with MTB specific drug resistance genes associated with drugs such as pyrazinamide, isoniazid and ethambutol. The database can be easily searched and browsed at <http://bicresources.jcbose.ac.in/ssaha4/drag>. DRAGdb also includes a BLAST search option to predict drug resistance related mutations. Comparison and analysis of mutations in DRAGs across bacterial species give a clear indication of two phylogenetic phenomena namely homoplasy and pleiotropy. Six genes (*gidB*, *gyrA*, *gyrB*, *rpoB*, *rpsL* and *rrs*) were associated with drug resistance not only in MTB but also in ESKAPE and other bacterial pathogens. For these genes, we analyzed coding regions using MSA where MTB H37Rv was used as reference genome. Some genes (*inhA*, *embB*, *katG* and *pncA*) were specific to MTB. The promoter regions of *inhA* and *pncA* were involved in drug resistance along with their genic regions. The study clearly indicates that under the stress of drug exposure, the response is not random. Instead it follows a defined pattern across bacterial communities.

## Methods

**Database implementation.** DRAGdb comprises of a single table where each mutation entry is uniquely identified with DRAGDB\_ID as the primary key. The NUCLEOTIDE\_POSITION, NUCLEOTIDE\_CHANGE, AMINOACID\_POSITION, AMINOACID\_CHANGE define the mutation point at both levels. The PUBMED\_ID provides PubMed identifier, hyperlink to PubMed database and ENSEMBL\_BACTERIA\_ID provides the gene identifier.

DRAGdb was developed using the Apache HTTP 2.2.15 web server and MySQL 5.1.69. The PHP 5.3.3, HTML, JavaScript and CSS were used to build the web interfaces of the database. The PHP-based web interfaces execute the SQL queries dynamically. It is freely accessible at <http://bicresources.jcbose.ac.in/ssaha4/drag>.

**Data curation.** The PubMed database (till March 2018) was searched for studies that reported at least one mutation in *rpoB*, *pncA*, *inhA*, *katG*, *embA*, *embB*, *embC*, *gidB*, *rpsL*, *rrs*, *gyrA* and *gyrB* associated with resistance to rifampicin, pyrazinamide, isoniazid, ethambutol, streptomycin and fluoroquinolones respectively in MTB, ESKAPE and other bacterial species. The literature was searched using advance search option of PubMed with the terms: “Gene name (Abstract/title) AND Resistance (Abstract/title) AND mutation (Abstract/title) AND/ NOT tuberculosis (Abstract/title)”. The combination of search terms helped to obtain instances with cross resistance and multiple resistances. In total, 2548 unique publications were obtained from this search. The publications that were missing full English text in public domain, or lacked relevant data or had ambiguous data were filtered out. Around 604 publications were systematically reviewed to obtain mutational information. All the mutations described in drug resistant bacterial strains in the literature were manually read, further curated and compiled in the database. The devised methodology is given as workflow in Supplementary File 1: Figure S3.

**Mutation data analysis with reference to MTB H37Rv.** All the gene mutations reported in the literature across bacterial species have different numbering systems (NS) thus leading to genetic location inconsistency and conflict. One of the examples of NS discrepancy is of *gyrA* in MTB, for which 4 different NS were found in the literature<sup>54</sup>. For better understanding and comparison across species of a single gene, *Mycobacterium tuberculosis* H37Rv was selected as reference organism, further multiple sequence alignment (MSA) was performed at amino acid codon level for each drug resistance gene to have single numbering system across all organisms. MSA was performed on on-line Clustal Omega platform using default iterated mBed-like Clustering Guide-tree<sup>55,56</sup>. The rationale for choosing MTB as reference genome was due to the fact that exposure of 3–6 antibiotics including broad spectrum antibiotics during TB treatment for 6 months results in known multiple drug resistance phenotypes. The MSA of the regions of interest for genes such as *gyrA*, *gyrB*, *rpoB*, and *rpsL* were shown in Supplementary File 1: Figures S1(A–D). The common reference number at the amino acid codons level of drug resistance genes across bacterial species helped in calculating frequency of mutated codon positions in DRAGdb. The frequency percentage was calculated using the following formulae –

$$F_{xi} = \frac{N_{xi}}{\sum_{i=j}^t N_{xi}} \times 100$$

where  $F_{xi}$  is the frequency percentage of  $i^{th}$  codon or nucleotide position in a gene of  $x^{th}$  group,  $x$  can be all organisms, *Mycobacterium*, ESKAPE pathogens or other bacteria.  $N_{xi}$  is the number of mutation entries of  $i^{th}$  codon or nucleotide position in the gene of  $x^{th}$  group in DRAGdb.  $\sum_{i=j}^t N_{xi}$  is the total number of mutation entries in the drug resistance determining region (DRDR) of the gene,  $j$  is the starting codon or nucleotide position and  $t$  is the end codon or nucleotide position of DRDR. The number of mutation entries was calculated based on report of a single mutation across various PubMed literature. We assume that the higher the number of publications reporting a particular drug resistance determining gene mutation, the higher is the confidence of that mutation entry.

**Functional effects of the mutations.** The functional effects of the unique SNPs in drug-resistance genes in different bacteria were predicted using PROVEAN webserver with Score thresholds for prediction as of –2.5.

The variants with score equal to or below of  $-2.5$  were considered “deleterious”, and the variants with score of above  $-2.5$  were considered “neutral”<sup>57</sup>.

**Blast search.** A customized BLAST database was created with wild type and mutated small nucleotide stretches of drug resistance determining regions of associated genes. The mutated sequences were modified wild type sequences with incorporation of single mutations enlisted in DRAGdb. *blastall*, a package for BLAST search was used<sup>58</sup>. *formatdb* utility from that package was used for converting nucleotide FASTA sequences to BLAST database. *blastn* program was used to find similar sequences to query sequences in the BLAST database.

**DRAGdb user interface.** The ‘HOME’ page of DRAGdb web interface provides two different search options: 1) keyword search: a single keyword can be searched specific to bacteria, resistant drugs, genes, geographical location or ‘ALL’ option to search in any category. 2) Advance search: three fields are present where bacteria and gene name are mandatory and drug name is optional. Both the search options will generate a table giving details of the mutations related to the search and also provide the number of specific entries. The DRAGdb result pages also contain hyperlinked Ensembl Bacteria IDs, PROVEAN score and PubMed IDs. To keep with the open access policy, the result table can be downloaded by the users. The ‘BROWSE’ page allows users to browse DRAGdb data in three categories: 6 drugs, 12 genes, and 126 bacterial species. It shows the comparison of DRAGdb data with other tuberculosis databases namely, TBDReaMDB and MUBII-TB-DB. The ‘Organisms’ section is further divided into 3 parts: ‘*Mycobacterium tuberculosis*’, ‘ESKAPE’ and ‘others’ which includes other bacterial species. The entries within the three categories are linked to DRAGdb table and provide specific results with details of the gene mutations. The nucleotide BLAST search with customized BLAST database is incorporated in the ‘TOOL’ page to determine whether the users input bacterial gene sequence is drug resistant. Users can define the ‘E-value’ for BLAST operation. The output page shows the user input sequence, the DRAGDB\_ID of the best hit, the BLAST score and E-value of the hit. ‘OTHER LINKS’ page is also included to help users find popular TB and antibiotic resistance related databases and webservers. To guide users through DRAGdb, a ‘HELP’ page is also presented in the online web server.

**Data visualization.** The bar plots for representation of frequency % of various codon level mutations of drug resistance genes across bacterial species were drawn using Microsoft office excel. The circular plots for representations of homoplasy and pleiotropy were drawn using ‘circlize’ R package<sup>59</sup>.

### Data availability

Data are available at <http://bicresources.jcbose.ac.in/ssaha4/drag/browse.php>. Supporting figures and tables are included in Supplementary Files 1–3.

Received: 14 February 2019; Accepted: 9 April 2020;

Published online: 02 June 2020

### References

- Krause, K. M., Serio, A. W., Kane, T. R. & Connolly, L. E. Aminoglycosides: An Overview. *Cold Spring Harb Perspect Med* **6**, <https://doi.org/10.1101/cshperspect.a027029> (2016).
- Rothstein, D. M. R., Alone and in Combination. *Cold Spring Harb Perspect Med* **6**, <https://doi.org/10.1101/cshperspect.a027011> (2016).
- Redgrave, L. S., Sutton, S. B. & Webber, M. A. & Piddock, L. J. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. *Trends Microbiol.* **22**, 438–445, <https://doi.org/10.1016/j.tim.2014.04.007> (2014).
- World Health Organization. *Antibiotic resistance*, <http://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance> (2018).
- Sommer, M. O. A., Munck, C., Toft-Kehler, R. V. & Andersson, D. I. Prediction of antibiotic resistance: time for a new preclinical paradigm? *Nat. Rev. Microbiol.* **15**, 689–696, <https://doi.org/10.1038/nrmicro.2017.75> (2017).
- Kim, J. S. & Wood, T. K. Tolerant, Growing Cells from Nutrient Shifts Are Not Persister Cells. *MBio* **8**, <https://doi.org/10.1128/mBio.00354-17> (2017).
- McKeegan, K. S., Borges-Walmsley, M. I. & Walmsley, A. R. Microbial and viral drug resistance mechanisms. *Trends Microbiol.* **10**, S8–14 (2002).
- Brauner, A., Fridman, O., Gefen, O. & Balaban, N. Q. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. *Nat. Rev. Microbiol.* **14**, 320–330, <https://doi.org/10.1038/nrmicro.2016.34> (2016).
- Crofts, T. S., Gasparrini, A. J. & Dantas, G. Next-generation approaches to understand and combat the antibiotic resistome. *Nat. Rev. Microbiol.* **15**, 422–434, <https://doi.org/10.1038/nrmicro.2017.28> (2017).
- Kumar, P. *et al.* Molecular Insights into Antimicrobial Resistance Traits of Multidrug Resistant Enteric Pathogens isolated from India. *Sci. Rep.* **7**, 14468, <https://doi.org/10.1038/s41598-017-14791-1> (2017).
- Lakin, S. M. *et al.* MEGARes: an antimicrobial resistance database for high throughput sequencing. *Nucleic Acids Res.* **45**, D574–D580, <https://doi.org/10.1093/nar/gkw1009> (2017).
- Pendleton, J. N., Gorman, S. P. & Gilmore, B. F. Clinical relevance of the ESKAPE pathogens. *Expert. Rev. Anti Infect. Ther.* **11**, 297–308, <https://doi.org/10.1586/eri.13.12> (2013).
- Quainoo, S. *et al.* Whole-Genome Sequencing of Bacterial Pathogens: the Future of Nosocomial Outbreak Analysis. *Clin. Microbiol. Rev.* **30**, 1015–1063, <https://doi.org/10.1128/CMR.00016-17> (2017).
- Sandgren, A. *et al.* Tuberculosis drug resistance mutation database. *PLoS Med.* **6**, e2, <https://doi.org/10.1371/journal.pmed.1000002> (2009).
- Flandrois, J. P., Lina, G. & Dumitrescu, O. MUBII-TB-DB: a database of mutations associated with antibiotic resistance in *Mycobacterium tuberculosis*. *BMC Bioinforma.* **15**, 107, <https://doi.org/10.1186/1471-2105-15-107> (2014).
- Coll, F. *et al.* Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genome Med.* **7**, 51, <https://doi.org/10.1186/s13073-015-0164-0> (2015).
- Samuelson, D. R., Welsh, D. A. & Shellito, J. E. Regulation of lung immunity and host defense by the intestinal microbiota. *Front. Microbiol.* **6**, 1085, <https://doi.org/10.3389/fmicb.2015.01085> (2015).
- Schuijt, T. J. *et al.* The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. *Gut* **65**, 575–583, <https://doi.org/10.1136/gutjnl-2015-309728> (2016).

19. Sze, M. A. *et al.* Changes in the bacterial microbiota in gut, blood, and lungs following acute LPS instillation into mice lungs. *PLoS One* **9**, e111228, <https://doi.org/10.1371/journal.pone.0111228> (2014).
20. Gupta, N., Kumar, R. & Agrawal, B. New Players in Immunity to Tuberculosis: The Host Microbiome, Lung Epithelium, and Innate Immune Cells. *Front. Immunol.* **9**, 709, <https://doi.org/10.3389/fimmu.2018.00709> (2018).
21. Pal, C., Bengtsson-Palme, J., Kristiansson, E. & Larsson, D. G. The structure and diversity of human, animal and environmental resistomes. *Microbiome* **4**, 54, <https://doi.org/10.1186/s40168-016-0199-5> (2016).
22. Feng, J. *et al.* Antibiotic resistome in a large-scale healthy human gut microbiota deciphered by metagenomic and network analyses. *Env. Microbiol.* **20**, 355–368, <https://doi.org/10.1111/1462-2920.14009> (2018).
23. Millie, C. S. *et al.* Ecology drives a global network of gene exchange connecting the human microbiome. *Nature* **480**, 241–244, <https://doi.org/10.1038/nature10571> (2011).
24. Fajardo-Cavazos, P. & Nicholson, W. L. Cultivation of *Staphylococcus epidermidis* in the Human Spaceflight Environment Leads to Alterations in the Frequency and Spectrum of Spontaneous Rifampicin-Resistance Mutations in the *rpoB* Gene. *Front. Microbiol.* **7**, 999, <https://doi.org/10.3389/fmicb.2016.00999> (2016).
25. Kiwaki, M. & Sato, T. Antimicrobial susceptibility of *Bifidobacterium breve* strains and genetic analysis of streptomycin resistance of probiotic *B. breve* strain Yakult. *Int. J. Food Microbiol.* **134**, 211–215, <https://doi.org/10.1016/j.ijfoodmicro.2009.06.011> (2009).
26. Wake, D. B., Wake, M. H. & Specht, C. D. Homoplasy: from detecting pattern to determining process and mechanism of evolution. *Science* **331**, 1032–1035, <https://doi.org/10.1126/science.1188545> (2011).
27. Walker, T. M. *et al.* Whole-genome sequencing for prediction of *Mycobacterium tuberculosis* drug susceptibility and resistance: a retrospective cohort study. *Lancet Infect. Dis.* **15**, 1193–1202, [https://doi.org/10.1016/S1473-3099\(15\)00062-6](https://doi.org/10.1016/S1473-3099(15)00062-6) (2015).
28. Guerillot, R. *et al.* Convergent Evolution Driven by Rifampin Exacerbates the Global Burden of Drug-Resistant *Staphylococcus aureus*. *mSphere* **3**, <https://doi.org/10.1128/mSphere.00550-17> (2018).
29. Poole, K. Bacterial stress responses as determinants of antimicrobial resistance. *J. Antimicrob. Chemother.* **67**, 2069–2089, <https://doi.org/10.1093/jac/dks196> (2012).
30. Baek, K. T. *et al.* Stepwise decrease in daptomycin susceptibility in clinical *Staphylococcus aureus* isolates associated with an initial mutation in *rpoB* and a compensatory inactivation of the *clpX* gene. *Antimicrob. Agents Chemother.* **59**, 6983–6991, <https://doi.org/10.1128/AAC.01303-15> (2015).
31. Sreevatsan, S. *et al.* Restricted structural gene polymorphism in the *Mycobacterium tuberculosis* complex indicates evolutionarily recent global dissemination. *Proc. Natl Acad. Sci. USA* **94**, 9869–9874 (1997).
32. Cole, S. T. *et al.* Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* **393**, 537–544, <https://doi.org/10.1038/31159> (1998).
33. Banerjee, A. *et al.* *inhA*, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science* **263**, 227–230 (1994).
34. Belanger, A. E. *et al.* The *embAB* genes of *Mycobacterium avium* encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. *Proc. Natl Acad. Sci. USA* **93**, 11919–11924, <https://doi.org/10.1073/pnas.93.21.11919> (1996).
35. Johnsson, K., Froland, W. A. & Schultz, P. G. Overexpression, purification, and characterization of the catalase-peroxidase KatG from *Mycobacterium tuberculosis*. *J. Biol. Chem.* **272**, 2834–2840 (1997).
36. Zhao, X. *et al.* Hydrogen peroxide-mediated isoniazid activation catalyzed by *Mycobacterium tuberculosis* catalase-peroxidase (KatG) and its S315T mutant. *Biochemistry* **45**, 4131–4140, <https://doi.org/10.1021/bi051967o> (2006).
37. Zhang, H. *et al.* Characterization of *Mycobacterium tuberculosis* nicotinamidase/pyrazinamidase. *FEBS J.* **275**, 753–762, <https://doi.org/10.1111/j.1742-4658.2007.06241.x> (2008).
38. Bush, K. & Jacoby, G. A. Updated functional classification of beta-lactamases. *Antimicrob. Agents Chemother.* **54**, 969–976, <https://doi.org/10.1128/AAC.01009-09> (2010).
39. Naas, T. *et al.* Beta-lactamase database (BLDB) - structure and function. *J. Enzyme Inhib. Med. Chem.* **32**, 917–919, <https://doi.org/10.1080/14756366.2017.1344235> (2017).
40. Srivastava, A., Singhal, N., Goel, M., Viradi, J. S. & Kumar, M. CBMAR: a comprehensive beta-lactamase molecular annotation resource. *Database* **2014**, bau111, <https://doi.org/10.1093/database/bau111> (2014).
41. Saha, S. B., Uttam, V. & Verma, V. u-CARE: user-friendly Comprehensive Antibiotic resistance Repository of *Escherichia coli*. *J. Clin. Pathol.* **68**, 648–651, <https://doi.org/10.1136/jclinpath-2015-202927> (2015).
42. Ezewudo, M. *et al.* Integrating standardized whole genome sequence analysis with a global *Mycobacterium tuberculosis* antibiotic resistance knowledgebase. *Sci. Rep.* **8**, 15382, <https://doi.org/10.1038/s41598-018-33731-1> (2018).
43. Doster, E. *et al.* MEGARes 2.0: a database for classification of antimicrobial drug, biocide and metal resistance determinants in metagenomic sequence data. *Nucleic Acids Res.* **48**, D561–D569, <https://doi.org/10.1093/nar/gkz1010> (2020).
44. Pal, C., Bengtsson-Palme, J., Rensing, C., Kristiansson, E. & Larsson, D. G. BacMet: antibacterial biocide and metal resistance genes database. *Nucleic Acids Res.* **42**, D737–743, <https://doi.org/10.1093/nar/gkt1252> (2014).
45. Gibson, M. K., Forsberg, K. J. & Dantas, G. Improved annotation of antibiotic resistance determinants reveals microbial resistomes cluster by ecology. *ISME J.* **9**, 207–216, <https://doi.org/10.1038/ismej.2014.106> (2015).
46. Gillespie, J. J. *et al.* PATRIC: the comprehensive bacterial bioinformatics resource with a focus on human pathogenic species. *Infect. Immun.* **79**, 4286–4298, <https://doi.org/10.1128/IAI.00207-11> (2011).
47. Gupta, S. K. *et al.* ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. *Antimicrob. Agents Chemother.* **58**, 212–220, <https://doi.org/10.1128/AAC.01310-13> (2014).
48. Liu, B. & Pop, M. ARDB—Antibiotic Resistance Genes Database. *Nucleic Acids Res.* **37**, D443–447, <https://doi.org/10.1093/nar/gkn656> (2009).
49. Alcock, B. P. *et al.* CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Res.* **48**, D517–D525, <https://doi.org/10.1093/nar/gkz935> (2020). <https://www.ncbi.nlm.nih.gov/pathogens/isolates/#refgene>.
50. Zankari, E. *et al.* PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens. *J. Antimicrob. Chemother.* **72**, 2764–2768, <https://doi.org/10.1093/jac/dkx217> (2017).
51. Lakin, S. M. *et al.* Hierarchical Hidden Markov models enable accurate and diverse detection of antimicrobial resistance sequences. *Commun. Biol.* **2**, 294, <https://doi.org/10.1038/s42003-019-0545-9> (2019).
52. Feldgarden, M. *et al.* Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. *Antimicrob. Agents Chemother.* **63**, <https://doi.org/10.1128/AAC.00483-19> (2019).
53. Maruri, F. *et al.* A systematic review of gyrase mutations associated with fluoroquinolone-resistant *Mycobacterium tuberculosis* and a proposed gyrase numbering system. *J. Antimicrob. Chemother.* **67**, 819–831, <https://doi.org/10.1093/jac/dkr566> (2012).
54. Clustal Omega < Multiple Sequence Alignment < EMBL-EBI. Ebi.ac.uk (2020). at <https://www.ebi.ac.uk/Tools/msa/clustalo/> EBI. Vol. 2018 (2017).
55. Sievers, F. & Higgins, D. G. Clustal Omega for making accurate alignments of many protein sequences. *Protein Sci.* **27**, 135–145, <https://doi.org/10.1002/pro.3290> (2018).
56. Choi, Y., Sims, G. E., Murphy, S., Miller, J. R. & Chan, A. P. Predicting the functional effect of amino acid substitutions and indels. *PLoS One* **7**, e46688, <https://doi.org/10.1371/journal.pone.0046688> (2012).

58. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. *J. Mol. Biol.* **215**, 403–410, [https://doi.org/10.1016/S0022-2836\(05\)80360-2](https://doi.org/10.1016/S0022-2836(05)80360-2) (1990).
59. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular visualization in R. *Bioinformatics* **30**, 2811–2812, <https://doi.org/10.1093/bioinformatics/btu393> (2014).

### Acknowledgements

We thank Prof. Joyoti Basu and Dr. Anupama Ghosh for critically reading the manuscript. AG would like to thank DBT, Govt. of India for DBT-BINC-JRF Fellowship. SS thank Bose Institute for intramural fund.

### Author contributions

A.G. and S.N. collected and compiled the data. A.G., S.N. and S.S. performed the data analysis and wrote the manuscript. S.S. conceived the idea and supervised the overall study.

### Competing interests

The authors declare no competing interests.

### Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41598-020-65766-8>.

**Correspondence** and requests for materials should be addressed to S.S.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020